Dr Leila Strickland became a mother when she was a few months away from completing her postdoctorate fellowship in cell biology at Stanford University. She spent the first three months of her sons life at home on maternity leave, relentlessly struggling to breastfeed. I was having a hard time producing enough milk. She never expected to find feeding her baby a greater challenge than advanced cytology.
My mom breastfed me and my sister until we were over two years old. All my life, Id fully embraced the proposition that breast milk is the best nutrition for a baby, and that this is what I would feed my baby. Lactation consultants, paediatricians and well-meaning friends told her to just keep trying. Because I was so unprepared for it, I found it really isolating. I felt like there was something wrong with me.
Eventually reluctantly Strickland decided to bottle-feed her baby with formula. It was convenient and practical, and made it possible for me to get more sleep, and for my husband to participate. In some ways I was able to be a better mom, and I was a lot happier, but I knew I was making a trade-off. I knew the product my child was getting was optimal for raising cows, that it didnt have the ideal nutrient composition. It was good enough but what mom is happy with good enough?
Eleven years later, Strickland has combined her experiences as both a stressed mother and a cell biologist in a way that could change how we feed our babies for ever: she has worked out how to make human breast milk without the human breast. Her startup, Biomilq, cultures breast cells in a lab farming them outside the body and collects the milk they secrete. The company calls it the mother of all patented technology and it has caught the eye of Bill Gates, who bought a $3.5m (2.7m) stake in Biomilq in June. Potentially, it could end the infant formula industry as we know it.
While the science shows breast is best helping cement the emotional connection between mother and child; providing optimal nutrition, antibodies and bacteria; reducing the risk of obesity and diabetes in adulthood breastfeeding can be a lottery. Many women find it straightforward and rewarding, but for others it is painful and demoralising. Sometimes babies have tongue-tie and wont latch on, or the mother has mastitis, or doesnt produce enough milk for the baby to put on the weight required to satisfy ever-watchful midwives and health visitors. Sometimes the baby is premature, or ill, and needs to be fed through a tube, or the mother is embarrassed about feeding in public, or needs to go back to work. Faced with these challenges, the most determined mothers might express milk with a pump; but pumping can be a time-consuming and often wretched experience.
For three years, I just had a really expensive science hobby that most people in my life thought was extremely weird
The other alternative is formula. But, as Strickland says, it is a trade-off. Although their composition has improved, infant formulas are generally made from cows milk and therefore have sugars, proteins and fats best suited to calves. Human milk contains hormones, antibodies and friendly bacteria, as well as unique proteins and sugars. Formula also has a substantial carbon footprint; it is made from products that depend on dairy farming, or the cultivation of palm oil or soy. Theres also the shame many mothers feel after they turn to the bottle: women who use formula after struggling with breastfeeding have been shown to experience greater levels of guilt than mothers who chose not to breastfeed from the start.
Founded in January 2020, Biomilq boasts that it is women-owned, science-led and mother-centred. Strickland is juggling running the lab with homeschooling her two children through lockdown; in our video call from her house in North Carolina, she is casually dressed in a sweatshirt, and I can hear the sound of plates being knocked off tables in far-off rooms as we speak.
Growing food in a lab is called cellular agriculture and Strickland describes her work as if it were a kind of farming. We start with these amazing cells that line a womans mammary gland, she explains. Using the same techniques that weve used for decades to grow cells outside the body, were able to reproduce the behaviour these cells have evolved over millions of years, to produce components in quantities that match the babys needs.
Scientists have long been culturing cells for biomedical research, but it was in 2013, when Maastricht Universitys Mark Post served up a lab-grown hamburger to food critics on live TV, that the idea of making food from cells entered the public consciousness. Since then, dozens of startups worldwide have begun to make meat in the same way. No animal has to suffer and there are seemingly endless possibilities, from cruelty-free foie gras to kosher bacon.
Seeing Posts burger consumed live was a pivotal moment for Strickland. It was obvious to her that milk had to be next, though it poses a different technical challenge. Those guys have to harvest every single cell they grow and turn it into a product, she says. Her product is the secretion rather than the cell. Just as dairy farmers have different priorities to beef farmers, Stricklands product demands that she keeps her cells alive and producing for as long as possible, instead of selling them off as soon as they mature.
She started to do homespun experiments with her husband, who has a background in chemistry and engineering: he designed the scaffold on which the cells are grown and kept separate from their secretions. They rented a small lab space and spent about $5,000 (3,827) on used equipment from eBay, but the experiments were expensive. We were choosing between feeding cells and feeding our children. We had to choose our children, Strickland laughs. They used the cheapest source of mammary cells they could find: cow udders bought for $20 (15) a piece from the bewildered manager of the nearest slaughterhouse, taken to the lab and minced up.
Strickland monitored their growth in different conditions, and when she thought shed come up with the optimal technique, started experimenting with human breast cells, bought from commercial suppliers who normally provide them for breast cancer research. But she had no budget to test if her cells were actually producing human milk. For the most part, between 2013 and 2016, I just had a really expensive science hobby that most people in my life thought was extremely weird.
Burnt out, she gave up her lab in 2016. But no one else seemed to be pursuing her idea and it nagged away. In 2019, Strickland decided to make one more serious stab at this experiment. A mutual friend introduced her to Michelle Egger, who would eventually become Biomilqs CEO. Egger has a background in food science and had been working at the Bill and Melinda Gates Foundation. I know how to grow cells but I dont know anything about how to grow a company, so Michelle brought that crucial expertise, Strickland says.
Egger and Strickland got a commercial lab to run a proof-of-concept experiment, growing cells for a month and collecting samples every day. In February 2020, the results were in: the cells were producing the unique proteins and sugars found in human breast milk. The breakthrough led to the $3.5m investment from Gates, which will allow them to scale up the process, and which has changed Stricklands life. Im really doing my dream, she says. I get emotional in our meetings, because its really personal for me.
The breast milk Strickland produces in her lab is different from the milk that comes out of a human breast. It cant change in response to a babys needs, as milk from a breast can (for example, being diluted on hotter days when the baby needs more fluids); it contains no hormones or bacteria from the mothers biome. Most significantly, it has no antibodies, because these are imported into the milk from the mothers blood, which disembodied cells cant do. Thats a part of breast milk we wont be able to replicate, Strickland says, matter-of-factly.
On an online breast milk market, requests are posted every hour, often next to a photo of a baby wide-eyed with hunger
She can afford to be relaxed about this, because Biomilqs market research suggests babies who drink their product will be getting breastfed anyway, and given Biomilq as a supplement. Those babies will be getting the antibodies from their own mother, then they will be getting a breast milk with a very similar composition when shes not able to breastfeed if she wants to go back to work, say, or sleep through the night. Their mission statement says their product is for women who need a little boost. Their target consumer is someone who is determined to breastfeed, but cant. Just like Strickland was.
But how liberating will lab-produced breast milk be? Its easy to imagine a scenario in which employers might be less willing to give women the space and time to breastfeed if a product like this exists. I do think we want to be careful and conscientious about things like that, Strickland says. We certainly wouldnt want to compromise any womans ability to breastfeed. She pauses. Any women who are at work and still trying to feed their babies breast milk are spending a good part of their day pumping. Thats what wed be targeting the pumping. Saving you from having to do that.
For Strickland, its about addressing the gulf between the expectations put on mothers and the reality. We want to celebrate breastfeeding, and encourage women to do it. Theres just not a great conversation going on about the challenges, she says. Most babies are not exclusively breastfed for six months [as recommended by the World Health Organization] and its not because women dont know or care about the benefits. Its because modern life really offers women no solution to achieve it.
***
The pressure not to accept the good enough provided by infant formula weighs heavily on mothers who want to breastfeed but are prevented from doing so by biology or circumstance. Its enough to have fuelled the growth of the underground online breast milk market. The invention of formula should have put an end to the practice of wet nursing; rather, the stigma attached to it has given rise to a new digital wet-nursing economy.
Services such as onlythebreast.com link up breast milk sellers with buyers, leaving it up to buyers to do their own screening. Searches can be narrowed down according to location, the age of the baby the milk has been produced for and whether the seller is following a specific diet: vegan, gluten-free or even paleo. The website advises that frozen expressed milk should be doubled bagged, wrapped in newspaper and put in a cooler with dry ice before being couriered to the recipient. It would set you back around 36 a day to feed the average month-old baby with milk bought here, priced at 1-1.50 an ounce, not including postage and packaging.
Of course, many women are happy to give their breast milk away for free. There are 15 hospital milk banks in the UK, providing screened, pasteurised donor milk, but it is destined for sick and premature babies in neonatal units. Mothers of healthy babies in search of breast milk often join one of Facebooks dozens of milk-sharing networks in hope of finding a nearby donor. The Human Milk 4 Human Babies UK Facebook group has more than 27,000 members. A new request for milk is posted every hour or so, often accompanied by photographs of tiny babies, wide-eyed with hunger.
The women posting on these forums have turned to social media out of desperation. One mother, who asked for donor milk to tide her four-week-old over while she works on topping up her supply, told me her failure to produce enough milk for him was an extremely painful experience. Everybody agrees that breast milk is a better option than formula.
Another mother began the search for breast milk a month before her second child was born. It was, she said, the best decision. She had tried everything to breastfeed her first baby, from renting a hospital-grade breast pump to taking drugs that might help boost lactation, but nothing worked. She now drives for at least an hour and a half every other week to collect frozen donor milk for her five-month-old son.
Human breast milk has nutritional ingredients formula simply doesnt, she said. I think of it as eating quality organic foods versus taking a synthetic supplement. It is the best thing I can give my child. When I sent a link to the Biomilq site, she replied, Wow. Finally. Shame [its] not available yet as I struggle to keep up with my sons demand. Will be forced to move on to formula.
Breast milk has become a symbol of optimal nutrition and optimal motherhood. But Joan Wolf, associate professor of womens and gender studies at Texas A&M University and author of Is Breast Best?, says women have been grossly misled about the extent of the advantages, because its impossible to disentangle the benefits of breast milk from the benefits of having a mother who wants to breastfeed.
This lab-grown breast milk could be very dangerous, reinforcing the idea that it really matters to breastfeed
You look at the sociology of breastfeeding, and the beliefs of women who breastfeed: they are determined to do everything they possibly can for their baby, she says. They are middle class; they feel theyve got to keep up with each other. Wolf argues that we increasingly feel we have a duty to reduce risk to ourselves or our families. Mothers must reduce any risk to an infant, no matter how small, and no matter the cost to the mother herself. Breast milk gets fetishised because of the risk element because its natural, and because it gives women a feeling of absolute power over their babies.
The availability of lab-grown milk wont assuage that desire to minimise all risks to your baby, Wolf says. One day we will have 15 different breast milks to pick from, each with different qualities. [Mothers] wont know which to pick. Theyll say, If I take this one the baby will get a gastrointestinal infection, or if I pick this one will they get cancer later. And this lab-grown breast milk could be very dangerous, because it could reinforce the idea that it really matters to breastfeed.
***
Stricklands work in the US may be groundbreaking, but she is not alone. She has an equally well-funded rival across the Pacific Ocean, backed by investors as diverse as British vegan private equity titan Jeremy Coller and Prince Khaled bin Alwaleed bin Talal Al Saud of Saudi Arabia.
We are the first biotech company in the world that is using cell-based methods to create milk, says Fengru Lin, founder and CEO of Singapores TurtleTree Labs, with the steely confidence of someone who is sure her company is not only first, but will be the best.
I speak to Lin and TurtleTrees chief strategist, Max Rye, in a video call to their respective homes in Lins native Singapore (Rye moved here from the US when they launched the company). Shes in an emerald blouse, her hair scraped back into a neat ponytail. He is every inch the relaxed American, leaning back on his sofa in a blue polo shirt. Before I even ask my first question, Rye tells me they want mothers to breastfeed. I always like to say, right at the beginning, we think its wonderful. We dont ever want that to stop. Theres nothing else like it, he says. Even though we can make human breast milk as a product, we are still far from the real thing.
Breast milk was an afterthought for TurtleTree Labs. The company began by culturing cows milk without the cow, and can now produce everything from sheeps and goats to camels milk, taking stem cells from freshly expressed milk and culturing them, instead of farming mammary cells as Biomilq does.
It started a few years ago when I was learning to make cheese as a hobby, Lin explains. It was difficult to find milk in Asia. There arent many cows in Singapore. She travelled around Indonesia and Thailand, and saw the problems of intensive dairy farming first-hand. Hormones and antibiotics are being pumped into the cows. As a result, the milk quality really suffers. They are impregnating the cow just to get her milk, again and again, every year. And the amount of methane cows create 37% of global emissions.
Lin was working as an account manager at Google at the time, and Rye, a tech executive, came to give a talk on new sustainable technologies. When he mentioned the startups growing meat from cells in a lab, Lins mind turned immediately to milk. Afterwards Fengru came up to me asking about milk, Rye says. And I thought, theres got to be someone working on this. There has to be. He holds his palms up in disbelief. But no, nobody was doing this.
They founded the company together in early 2019, and say it was feedback from dairy companies that prompted them to branch out into breast milk. The folks who provide milk in the stores are the same people who provide the raw ingredients for infant formula, Rye says. They approached us and said, Listen, youve got something really interesting: if you can make human milk, you can transform the way infant formula is done. We realised, this is where the demand is. Its also where the big money is: customers are used to paying a lot more for infant formula than they are for cows milk.
Instead of producing and bottling its own breast milk, TurtleTree Labs plans to licence its technology to existing formula companies. Rye wont tell me the names, only that they are four of the five biggest in the world.
There are huge regulatory hurdles to be crossed before lab-grown breast milk can go on sale, but Rye and Lin say getting approval for its individual components will be more straightforward. And they are thinking very broadly about possible consumers: elderly people and cancer patients may one day drink their breast milk or parts of it.
Early indications show certain bioactive proteins or complex sugars in human milk could be good for senior care and adult health, Lin says. Geriatric patients can have similar issues with their digestive system as infants, and early studies have shown certain compounds in breast milk may impede the growth of some cancers. But the benefits are under-researched: there isnt enough spare human milk to be giving it to adults on a clinically significant scale, and convincing them to try it is a challenge.
As soon as those sugars and proteins get regulatory approval, though, they can be added to existing infant formulas bringing them closer to breast milk than ever. TurtleTree expect that to happen as early as next year.
***
Strickland balks at the idea of working with the formula industry. Theres already distrust of these companies, the Nestls and Abbotts of the world, she says. We think its important to bring this product to market with as much credibility and authenticity as possible, as women and mothers and scientists ourselves. Our customers will appreciate seeing it come from us, rather than them.
Biomilqs initial plan is as eye-catching as the product itself: they are going to produce customised breast milk for early adopters, grown from the customers own cells. Moms would go through a fine needle biopsy procedure during their pregnancy, Strickland explains. That cell sample would be sent to us so we could start growing it up and producing milk. And then when shes ready, we can start shipping it to her.
I wasnt expecting to hear this: taking cells from pregnant women suggests that Biomilq is not solely for women who are having trouble breastfeeding but is also geared to those who assume they will need help before their baby even arrives. And its going to be very expensive, Strickland says: That would go at a pretty high price point, as a custom service.
But the initiative is more about demonstrating the potential of the product than the beginning of a business model, she says. We aim to generate an evangelised group of moms, parents and caregivers, who are excited enough to make that initial level of commitment.
It is difficult to envisage a way that breast milk grown in a lab can be anything other than an elite product. TurtleTree Labs estimates their milk costs $30 (23) a litre to produce, and even if that figure comes down dramatically (as they expect it to), the technology involved will always be more expensive than dairy-based formula. While breastfeeding is free, it is rarely compatible with full-time employment. A product like this will give those who can afford it either a nutritional edge, or a professional one.
Isnt this just going to be for very wealthy women? And wont it give them even greater advantages than they already enjoy?
We do not want this to be a product that perpetuates inequalities, Strickland replies, firmly. Thats something we think a lot about. Making this widely accessible is very much a part of our long-term plan. For instance, Biomilq is exploring ways employers might be able to subsidise the product for their staff although this raises further concerns that employers might expect nursing mothers to return to work earlier. Its a bit like a game of whack-a-mole: you push down on one problem and something pops up on the other side, Strickland concedes.
It may be many years before we can go to the supermarket and buy a bottle of breast milk. But the existence of companies such as TurtleTree Labs and Biomilq could well be a symptom of a problem, rather than a solution. In the wrong circumstances, their products could be used to stop women from breastfeeding in public, or to make formula feeding even more taboo. If women were more supported in breastfeeding, less ashamed of using the good enough dairy-based formula and less judged in general, then breast milk grown in a lab might not be necessary.
Strickland thinks once her product is on the market, it will be less easy to judge women for how they feed their babies. A mom sitting there feeding a bottle of our milk will look the same as a mother with a bottle of formula or her pumped milk. It would be indistinguishable, she says. Plus lab-grown milk is already provoking much-needed discussions about what we think is natural. If nothing else, I consider Biomilq already a success because we get to participate in these conversations.
Its hard to argue with that. But whether lab-grown breast milk changes the conversation for the better depends on who is making it, and who gets to use it. This invention may be Stricklands baby, but she cant control what it will grow into.
Jenny Kleeman is the author of Sex Robots & Vegan Meat: Adventures At The Frontier Of Birth, Food, Sex & Death (Picador).
Visit link:
I want to give my child the best: the race to grow human breast milk in a lab - The Guardian
- The therapeutic potential of stem cells - PubMed Central (PMC) - November 12th, 2024
- Stem Cell Therapy Market Is Projected To Achieve A Market Value Of USD 3.40 Bn. By 2030, Reflecting A Robus... - WhaTech - October 18th, 2024
- Doctor who provided ineffective stem cell therapies disciplined 6 years after investigation began - CBS Chicago - October 15th, 2024
- Study reveals the benefits and downside of fasting - Big Think - September 28th, 2024
- Tiny vesicles from umbilical cord blood may have therapeutic benefit - Parkinson's News Today - September 28th, 2024
- The Stem Cell Solution Review: Is This Program the Future of Anti-Aging and Recovery? - Enumclaw Courier-Herald - September 28th, 2024
- Cell and Gene Therapy Research To Benefit From New Stem Cell Collection Center - Technology Networks - September 25th, 2024
- Stem Cell Restore: A Full Review of Its Role in Promoting Regeneration and Vitality - Islands' Sounder - September 18th, 2024
- Is fasting good for you? A new study reveals some hidden risks and benefits of the practice - Business Insider India - August 31st, 2024
- Study reveals the benefits and downside of fasting - MIT News - August 27th, 2024
- Scilex Holding Company Announces the U.S. Patent and Trademark Office Will Be Issuing New ELYXYB® Patent Related to the Treatment of Acute Pain - August 22nd, 2024
- Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients - August 22nd, 2024
- Orion Corporation: Managers’ transactions – Niclas Lindstedt - August 22nd, 2024
- PharmaTher’s Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) Proteins - August 22nd, 2024
- BRIGHT GREEN EMBARKS ON MAJOR PARTNERSHIP WITH BENUVIA PHARMACEUTICALS. WILL SUPPLY PHARMA EXPERT WITH AMERICAN MADE RAW MATERIALS FROM ITS INDUSTRY... - August 22nd, 2024
- Eyenovia Announces Pricing of $5.14 Million Public Offering - August 22nd, 2024
- Firefly Neuroscience Forms Strategic Partnership with Neurology Consultants of Dallas (NCD) to Enhance Early Detection Efforts and Disease Management... - August 22nd, 2024
- Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment - August 22nd, 2024
- SIGA Announces New Contract Awarded by U.S. Department of Defense for the Procurement of $9 Million of TPOXX® - August 22nd, 2024
- MDxHealth Reports Q2 and Half Year 2024 Results - August 22nd, 2024
- Bavarian Nordic Receives 440,000 Dose Contract to Supply Smallpox and Mpox Vaccines for Undisclosed European Country - August 22nd, 2024
- Brains Bioceutical Set to Achieve One of the World’s First CEP for Cannabidiol Certification with the European Directorate for the Quality of... - August 22nd, 2024
- Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility - August 22nd, 2024
- Certara to Participate in Upcoming Investor Conferences - August 22nd, 2024
- Orion Corporation: Managers’ transactions – Satu Ahomäki - August 22nd, 2024
- Bavarian Nordic Announces First Half 2024 Results - August 22nd, 2024
- BioCryst to Present at Upcoming Investor Conferences - August 22nd, 2024
- Zymeworks Announces Participation in Upcoming Investor Conferences - August 22nd, 2024
- MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update - August 14th, 2024
- Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan - August 14th, 2024
- Shock Top and Gator Athletics Partner to Introduce First-Ever Craft Beer Sponsorship of the Florida Athletic Department - August 14th, 2024
- IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update - August 14th, 2024
- Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates - August 14th, 2024
- Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders - August 14th, 2024
- Evaxion Announces Business Update and Second Quarter 2024 Financial Results - August 14th, 2024
- Galera Announces Board Approval of Complete Liquidation and Dissolution - August 14th, 2024
- Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update - August 14th, 2024
- Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - August 14th, 2024
- Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research - August 14th, 2024
- CorMedix Inc. Reports Second Quarter and Six Month 2024 Financial Results and Provides Business Update - August 14th, 2024
- Panavance Therapeutics Announces Foundational Publication of Misetionamide (GP-2250) in Ovarian Cancer in the Journal, Cancer Medicine - August 14th, 2024
- Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors - August 14th, 2024
- Veralox Therapeutics Announces EMA Orphan Drug Designation for VLX-1005 - August 14th, 2024
- Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic... - August 14th, 2024
- Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results - August 14th, 2024
- Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons - August 14th, 2024
- Atsena Therapeutics Receives Rare Pediatric Disease Designation from the U.S. FDA for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis - August 14th, 2024
- Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates... - August 14th, 2024
- What Is Stem Cell Therapy? How Does It Work? - ThePrint - August 6th, 2024
- New Study Shows Short-Term Benefits of Stem Cell Therapy for MS Patients, But Long-Term Efficacy Remains Unclear - Managed Healthcare Executive - July 26th, 2024
- Cord Blood Awareness Month: Advantages of cord blood banking, things to keep in mind - Moneycontrol - July 10th, 2024
- Neural Stem Cell Plasticity: Advantages in Therapy for the Injured Central Nervous System - Frontiers - June 28th, 2024
- Harnessing benefits of stem cells for heart regeneration | ASU News - ASU News Now - June 21st, 2024
- 'Didn't know this would be possible': Autistic teen's mom on stem cell therapy benefits - WZTV - May 6th, 2024
- John Cleese says he's been spending 17,000 annually on stem cell therapy to 'buy a few extra years' - Yahoo News UK - April 24th, 2024
- Promethera Bets Liver-Derived Stem Cells Will Offer Benefits In NASH - Scrip - April 24th, 2024
- Stem Cell Therapies: Is This The Future Of Wellness? - Grazia USA - April 20th, 2024
- Signal of Benefit for Stem Cell Therapy in Progressive MS - Medscape - March 7th, 2024
- The Controversies Surrounding Stem Cell Therapy for Autism - The Portugal News - February 24th, 2024
- Benefits of Stem Cell Therapy - News Channel 5 Nashville - February 7th, 2024
- What is Stem Cell Therapy & How It Helps Others - Publicist Paper - January 31st, 2024
- A guide to stem cell therapy in Thailand - Thaiger - January 4th, 2024
- Half of pediatric patients with aHUS benefit from Soliris after... - AHUS News - December 21st, 2023
- Real world analysis on the determinants of survival in primary ... - Nature.com - December 5th, 2023
- The Best Beauty Gifts According To People Who Really Know Skin Care - HuffPost - December 5th, 2023
- The Eyepopping Factory Construction Boom in the US - WOLF STREET - December 3rd, 2023
- Benefit of Neoadjuvant Therapy Illustrated During ESMO Congress ... - Targeted Oncology - December 1st, 2023
- Benefits Outweigh Risks as FDA Inspects CAR-T Cell Therapy ... - Curetoday.com - December 1st, 2023
- Review What Real Cavityn Customers Say About Benefits and Side ... - Seattle Weekly - December 1st, 2023
- 'There is a Scientific Fraud Epidemic' - Slashdot - Slashdot - December 1st, 2023
- 15 Best Hydrating Serums to Soothe Any Skin Type 2023 - Town & Country - December 1st, 2023
- Innovations in Cosmetic Dermatology: A Glimpse into the Future - APN News - December 1st, 2023
- FDA Probes New Cases of Cancer That May Stem From Cancer Cell ... - MedCity News - November 29th, 2023
- Use of plant stem cells in topical formulations on the rise - CosmeticsDesign.com USA - November 29th, 2023
- Stem cell-based treatment controls blood sugar in people with Type ... - EurekAlert - November 29th, 2023
- Biologics Market is projected to grow at a CAGR of 8.5% by 2034: Visiongain - Yahoo Finance - November 29th, 2023
- Scientists devise new technique that can pinpoint the causes and ... - EurekAlert - November 29th, 2023
- Global Advanced Therapy Medicinal Products Market is on the brink ... - PharmiWeb.com - November 29th, 2023
- Introducing Orgavalue - The 2023 EIT InnoStars Awards winner - EU-Startups - November 29th, 2023
- Episode 160: Euan Ashley discusses precision medicine and the ... - IHMC - November 29th, 2023
Recent Comments